Back to top
more

Medtronic (MDT)

(Delayed Data from NYSE)

$92.88 USD

92.88
6,636,881

+1.64 (1.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $92.94 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed the most recent trading day at $88.81, moving +1.57% from the previous trading session.

Zacks Equity Research

Medtronic's (MDT) Study Shows Positive Results of TDD Use (revised)

by Zacks Equity Research

The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.

Zacks Equity Research

Medtronic's (MDT) Study Shows Positive Results of TDD Use

by Zacks Equity Research

The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.

Zacks Equity Research

Medtronic (MDT) Inks Value-Based Deal for Guardian Connect

by Zacks Equity Research

Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.

Zacks Equity Research

Medtronic's New Data for HVAD System to Boost CRHF Segment

by Zacks Equity Research

Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.

Zacks Equity Research

Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry

by Zacks Equity Research

Nevro's (NVRO) international sales get affected by weakness in Australia.

Zacks Equity Research

Medtronic's Diabetes Arm Grows Strong, Rising Costs Ail

by Zacks Equity Research

Medtronic (MDT) is highly optimistic about its foray into the $1-billion standalone CGM market with its Guardian Connect.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, IBM, Medtronic, lululemon and Carnival

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, IBM, Medtronic, lululemon and Carnival

Mark Vickery headshot

Top Analyst Reports for Chevron, IBM & Medtronic

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), IBM (IBM) and Medtronic (MDT).

Zacks Equity Research

Medtronic Unveils MedTech Innovation Accelerator in China

by Zacks Equity Research

The MedTech Innovation Accelerator is a collaborative initiative on part of Medtronic (MDT) to foray into the Chinese med-tech innovation market via venture investments, incubation and acceleration.

Zacks Equity Research

Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results

by Zacks Equity Research

The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.

Zacks Equity Research

Edwards Lifesciences Presents Positive Partner 3 Trial Data

by Zacks Equity Research

Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.

Zacks Equity Research

Why Is Medtronic (MDT) Down 1.2% Since Last Earnings Report?

by Zacks Equity Research

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Medtronic (MDT) Releases Encouraging Evalut TAVR Result

by Zacks Equity Research

Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.

Zacks Equity Research

Zacks.com featured highlights include: Lexicon, Medtronic and NetApp

by Zacks Equity Research

Zacks.com featured highlights include: Lexicon, Medtronic and NetApp

Tirthankar Chakraborty headshot

3 Stocks That Flaunt Solid Earnings Acceleration

by Tirthankar Chakraborty

Studies show that majority of successful stocks see acceleration in earnings before a positive stock price movement.

Zacks Equity Research

Medtronic's Mazor Robotics Aid Growth, Rising Costs Ail

by Zacks Equity Research

We are upbeat about the recently-concluded buyout of Mazor Robotics, which is likely to solidify Medtronic's (MDT) position in the spine surgery space.

Zacks Equity Research

Medtronic Launches Grafton DBM Bone Grafting Product in Japan

by Zacks Equity Research

Grafton DBM to strengthen Medtronic's (MDT) foothold in Japan.

Zacks Equity Research

Medtronic Gets FDA Approval for Accurian RF Ablation Platform

by Zacks Equity Research

Medtronic's (MDT) RF ablation platform will use radio waves to provide relief from chronic pain.

Zacks Equity Research

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

Zacks Equity Research

Stryker Expands Acquisition Portfolio With Arrinex Buyout

by Zacks Equity Research

Stryker's (SYK) latest buyout is expected to boost its Neurotechnology & Spine business.

Zacks Equity Research

Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry

by Zacks Equity Research

Integer Holdings (ITGR) holds a solid position in the MedTech space but is still exposed to competition.

Kevin Cook headshot

Bull of the Day: Tandem Diabetes Care (TNDM)

by Kevin Cook

FDA approval of its latest smart insulin pump has revived investor faith in shares that once traded above $300

Zacks Equity Research

Intuitive Surgical Gets FDA Nod for Ion Endoluminal System

by Zacks Equity Research

The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.

Zacks Equity Research

Company News For Feb 20, 2019

by Zacks Equity Research

Companies in the news are: AAP, MDT, HSBC and JELD